New pricing models could improve access to innovative cancer drugs
A consensus panel has concluded that the NHS could improve patient access to new cancer drugs by varying the price it pays for different medicines depending on what disease they are used to treat.
November 10, 2020
by pharmatimes
NICE argue for more histology-independent cancer drug evidence
Staff at NICE have co-authored a paper which suggests that new, histology-independent cancer treatments require more clinical evidence before approval recommendation by the institution.
January 13, 2020
by europeanpharmaceuticalreview
Century Therapeutics secures $250m to develop cancer drugs
Versant Ventures’ Century Therapeutics has secured $250m to develop allogeneic immune cell therapies for the treatment of cancer patients.
July 4, 2019
by pharmaceutical-technology
Novartis sees Saudi Arabia as promising market for producing its cancer drugs
Novartis may be struggling a bit in the U.S. with cancer drug launches, but it has a new market it can now explore––Saudi Arabia.
May 9, 2019
by fiercepharma
IGEM gets further funding for cancer drugs
IGEM Therapeutics has received a £750,000 grant from Innovate UK Biomedical Catalyst Primer Award.
April 4, 2019
by pharmatimes
Doctor payments drove scripts for cancer drugs from Pfizer, Novartis and more
Critics often target physicians who receive money from pharma, but the exact influence those payments have on prescribing is up for debate. In oncology, at least, it’s not one-off payouts but consistent compensation that's most likely to sway prescribing
February 24, 2019
by fiercepharma
AstraZeneca rides high on sales rebound after cancer drugs, China once again pull through
It's confirmed: AstraZeneca's outperforming fourth-quarter results show it is indeed back on the growth track, thanks to cancer drugs Tagrisso and Lynparza—and once again, China.
February 24, 2019
by fiercepharma
Genentech gets FDA priority review for two cancer drugs
Genentech, a subsidiary of Roche, has secured priority review status from the US Food and Drug Administration (FDA) for two of its oncology drugs, entrectinib and polatuzumab vedotin.
February 20, 2019
by pharmaceutical-technology
Study may explain why once-promising cancer drugs failed
Nearly two decades after a class of once-promising cancer drugs called MMP inhibitors mysteriously failed in clinical trials
January 29, 2019
by worldpharmanews
Special Report—2 years after sluggish 2016, new drug approvals hit their stride in 2018
If in 2017, the FDA was trying to make up for lost time, the agency went into overdrive in 2018, approving more than 50 new molecular entities.....
January 4, 2019
by fiercebiotech
No peak in sight: Cancer marketing spreads across media landscape, from TV to digital
The move to mainstream cancer advertising began several years ago with Bristol-Myers Squibb’s big TV campaign for Opdivo, followed by competitor Merck & Co. for its rival, Keytruda.
December 25, 2018
by fiercepharma
No peak in sight: Cancer marketing spreads across media landscape, from TV to digital
The move to mainstream cancer advertising began several years ago with Bristol-Myers Squibb’s big TV campaign for Opdivo, followed by competitor Merck & Co. for its rival, Keytruda. Both put out broad and hopeful
December 20, 2018
by fiercepharma